Role of extracellular vesicles in chronic lung disease

Anne Trappe,1,2 Seamas C Donnelly ,3 Paul McNally ,2,4 Judith A Coppinger1,2

ABSTRACT
To explore the role of extracellular vesicles (EVs) in chronic lung diseases.
EVs are emerging as mediators of intercellular communication and possible diagnostic markers of disease. EVs harbour cargo molecules including RNA, lipids and proteins that they transfer to recipient cells. EVs are intercellular communicators within the lung microenvironment. Due to their disease-specific cargoes, EVs have the promise to be all-in-one complex multimodal biomarkers. EVs also have potential as drug carriers in chronic lung disease. Descriptive discussion of key studies of EVs as contributors to disease pathology, as biomarkers and as potential therapies with a focus on chronic obstructive pulmonary disorder (COPD), cystic fibrosis (CF), asthma, idiopathic pulmonary fibrosis and lung cancer. We provide a broad overview of the roles of EV in chronic respiratory disease. Recent advances in profiling EVs have shown their potential as biomarker candidates. Further studies have provided insight into their disease pathology, particularly in inflammatory processes across a spectrum of lung diseases. EVs are on the horizon as new modes of drug delivery and as therapies themselves in cell-based therapeutics.
EVs are relatively untapped sources of information in the clinic that can help further detail the full translational nature of chronic lung disorders.

INTRODUCTION
What are EVs?
Extracellular vesicles (EVs) are lipid-membrane bound vesicles released from almost all cell types and an increasing abundance of literature has demonstrated the numerous roles EVs play in intercellular communication and disease pathogenesis.1 2 The cargo of EVs largely consists of miRNA, proteins and lipid molecules which they transfer to recipient cells.3 Chargaff and West first reported on the potential existence of EVs in 1946 describing the presence of ‘lipoproteins of very high particle weight’ in serum.4 Further studies described lipid-rich particles originating from the granules of platelets that accelerate coagulation.5 6 In the 1980s, Harding et al7 reported on multivesicular endosomes which fused with the plasma membrane of reticulocytes and released cargo into the extracellular space. Numerous studies were then undertaken to better understand the vesicle trafficking process being displayed in numerous cell types.8-10 Small vesicles emanating from the intracellular secretion pathway or multivesicular bodies became known as exosomes with larger particles shed from the plasma membrane described as microparticles.
The International Society for Extracellular Vesicles (ISEV) currently provides guidelines on categorising EVs. The minimal information for studies of extracellular vesicles (MISEV) paper published by ISEV summarises the difficulty in including biogenesis and origin as classifications for EV subtypes as consensus has not yet been reached on appropriate markers.11 Doyle and Wang make the argument that markers associated with vesicle formation should be used with nomenclature such as exosome and microvesicle.12 According to MISEV, there are three appropriate ways to subcategorise EVs (1) size alone, for example, small EVs, medium/large EVs (2) by markers, for example, CD81±EVs or (3) by known cellular origin, for example, from breast cancer cell culture.11
Table 1 below summarises the different EV subcategories encompassing their definition by size and biogenesis with indicative markers. An important caveat noted (*) is that there is cross sectionality in markers for vesicles which have similar exit strategies.
Cellular origin of EVs is particularly important in the clinical setting. MISEV provides guidelines on marker proteins which are cell/tissue-specific, table 2 summarises these. The inclusion of cellular origin has expanded the EV field to include other large vesicles such as oncosomes. Oncosomes carry distinct protein cargo and are considered to be a separate functional class of tumour-derived vesicles.13

Table 1 Guide on extracellular vesicle (EV) subcategories by size, formation and formation-associated markers

<table>
<thead>
<tr>
<th>EV category</th>
<th>Size (nm)</th>
<th>Formation</th>
<th>Marker</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exosome (small EV)</td>
<td>30–150</td>
<td>Endosome fuses with the plasma membrane and releases exosome</td>
<td>ESCRT and associated proteins</td>
</tr>
<tr>
<td>Microvesicle (medium/large EVs)</td>
<td>100–1000</td>
<td>Bud directly from the plasma membrane</td>
<td>Cytoskeletal and plasma membrane proteins (actinin, tetraspanins)*</td>
</tr>
<tr>
<td>Apoptotic body (larger EVs)</td>
<td>50–5000</td>
<td>Released by cells undergoing apoptosis</td>
<td>Proteins associated with the nucleus, Golgi, endoplasmic reticulum and other cellular organelles</td>
</tr>
</tbody>
</table>

*indicates markers which are used in more then one subcategory
ESCRT, endosomal sorting complexes required for transport.
In this review, we focus on EVs as both biological mediators of intercellular communication and biomarkers of disease, particularly in response to respiratory stressors in COPD, CF, asthma, idiopathic pulmonary fibrosis (IPF) and lung cancer.  

**METHODS OF EV ISOLATION AND ANALYSIS**

**Isolation**
EV isolation methods commonly exploit the physical or chemical properties of EVs. A challenge within EV research can be to obtain well-defined EV fractions of high quantity and purity to facilitate analytical characterisation. Table 3 summarises the most commonly used approaches and provides potential advantages/disadvantages of each. 

One of the biggest difficulties of EV research is the relatively long sample isolation times and suffer from lower yield and purity. Therefore, combined isolation/analysis systems are gaining traction and are of particular benefit for use in the clinical setting. One such system is the NanoView which uses a 'lab-on-a-chip' set-up, with EV antibodies immobilised on silicon chips. The benefit of a system such as this is that; small volumes (35 μL) of unprocessed biological samples are used, without prior isolation. However, this system is limited, as prior knowledge of the target protein is required and limits exploratory characterisation.

**Analysis**
Characterisation of individual EVs can be achieved using different instruments. Nanoparticle tracking analysis (NTA) based on the illumination of nanoparticles in suspension with a laser beam is one of the most widely used methods of establishing the size and quantity of EVs in a sample. Resistive pulse sensing (RPS) is an increasingly common technique for determining the size and distribution of EVs. RPS allows for accurate size determination of single particles by measuring the change in resistivity as a particle of a certain size passes through a pore. However, the method is limited by the pore size range. Flow cytometry is another frequently used technique for single-particle analysis, particularly in clinical settings. Benefits of this technique over others, such as NTA, are that it incorporates a number of detection modes and arguably provides a more accurate analysis due to user-defined thresholds.

Multifaceted ‘omics’ approaches which often include mass spectrometry (MS) (proteome, lipidome) and RNA sequencing analysis (transcriptome) have successfully enabled profiling of the EV in chronic lung diseases. RNA-Seq and microarrays are two of the most commonly used methods to sequence the transcriptome. Specific studies analysing RNA profiles within EVs are highlighted in the disease sections. MS is a developing area used to characterise the protein and lipid content of EVs. Accurate protein identification and quantitation have dramatically advanced due to high-performance MS technologies. Bottom-up proteomics approaches which involve the proteolytic digestion of proteins before MS analysis have enabled the identification of thousands of proteins in EVs. A bottom-up proteomic strategy is highlighted in figure 1. Alternative strategies such as top-down proteomics, which sequences intact proteins without the need for proteolytic digestion and targeted proteomic approaches such as multiple reaction monitoring also hold promise in EV research.

Proteomic profiling of EVs has successfully identified markers of acute exacerbation in COPD and unique protein fingerprints at different ages in persons with CF (PWCF), demonstrating the potential of EVs as markers for disease severity. MS analysis of EVs has successfully identified differential proteomes in patients with lung adenocarcinoma (ADC). Additionally, EVs isolated from nasal lavage fluid of asthmatic donors exhibited unique proteomes compared with controls.

Lipidomics involves the specific characterisation of the lipid profile of a sample. As EVs are encapsulated in a lipid bilayer, understanding their lipid content and their potential as biomarkers is of increasing interest in lung disease. Both targeted or global MS analysis of lipids can be performed using high-resolution mass analysers enabling the identification of lipid species by accurate mass. A study on the role of CF-EV derived sphingolipids in inflammation showing that the lipid profile of CF-EVs was significantly different compared with controls. Another study characterising the lipidome of EVs isolated from BALF from asthmatics and healthy controls identifying unique lipid EV profiles in patients with asthma.

**EVs as mediators of intercellular communication in the lung**
It has been well established that EVs play a significant role in cellular communication. Cell-to-cell communication involves the exchange of signals between cells through physical contact or chemical messengers. EVs have been identified as one of the main mediators of intercellular communication, facilitating the exchange of information between cells and the microenvironment.

The lung is a unique organ providing defence and against viral and bacterial pathogens. Defence against respiratory pathogens requires communication between structural and immune cells. The lung airway epithelium acts as both a physical barrier and stimulates innate and adaptive immune mechanisms important for maintaining lung homeostasis. EVs play a role in maintaining the lungs unique microenvironment’s homeostasis.
through intercellular communication. Mast cell-derived EVs have been shown to exhibit TGF-β on their surface and to induce epithelial–mesenchymal transition in airway epithelial cells within the lung. The presence of cytokine suppressor molecules in CD8α+CD11c+ lung EVs and alveolar macrophage-derived EVs contributed to regulating immune balance in the respiratory tract in asthma and COPD models. A role for EVs in proinflammatory signalling is described further in this review and has been the topic of other reviews and studies. The source of EVs within the lung has a significant contribution to the message they carry. Endogenous sources of EVs in the respiratory tract include epithelial cells and haematopoietic cells such as eosinophils, monocytes, macrophages and neutrophils. However, this is not an exhaustive list; EVs can be shed from endothelial cells. Zhao et al. demonstrated damaged pulmonary artery endothelial cells release an abundance of EVs. Bronchial epithelial cells are a primary source of reactive proinflammatory EVs in the lungs as they are most frequently exposed to insult and injury. EVs can also be released from bacterial sources. Exogenous bacterial EVs, expressed by pathogens in the lung, can create optimum growing conditions, encourage pathogen proliferation and prevent host immune responses.

**EVs as biomarkers in lung disease**

EVs can be found and isolated from most biological fluids in clinical disease cohorts. In respiratory research, bronchial lavage fluid (BALF) and blood are some of the more frequently studied sources of EVs. In chronic lung inflammatory disease, stress-induced EVs are correlated to pathogenesis. Examples of
such studies are outlined within the individual disease sections. Chronic pulmonary disorders are among the most frequent causes of death, claiming the lives of at least four million people annually around the world.\textsuperscript{55, 56} Shared characteristics of chronic lung disease are progressive reduced lung function and inflammation. Clinical symptoms include cough, chest tightness, shortness of breath and mucus production. Acute exacerbations of chronic lung disease\textsuperscript{57} are often triggered by infection and contribute to disease progression and disease-associated mortality.\textsuperscript{58}

There is a knowledge gap in the management of chronic lung diseases, including early identification, diagnostic biomarkers, and treatments.\textsuperscript{58, 59} Biomarkers can be used as indicators of the presence and severity of a disease. They can help us understand the cause and progression of a disease, achieve early prognosis or predict treatment outcome. The search for useful biomarkers in the clinic can be difficult, with many biomarkers failing at verification and validation stages before they enter clinical practice.\textsuperscript{59} Many studies have been limited to examining the relationship between individual biomarkers and cross-sectional outcomes.\textsuperscript{60} However, recent investigations demonstrated that using multiple biomarkers can be more predictive of cross-sectional and longitudinal COPD outcomes.\textsuperscript{61}

Due to EV cargoes’ disease-specific nature, these intercellular communicators can be an all-in-one complex multimodal biomarker.\textsuperscript{62} Changes in the number and content of EVs have been reported during exacerbation in COPD, asthma and CF.\textsuperscript{63, 64} EVs as therapeutic tools in lung disease

EVs have the potential to be novel drug delivery vehicles. Liposomal drug delivery systems, such as doxorubicin, a Food and Drug Administration (FDA)-approved chemotherapeutic, are highly effective in reducing the toxic effects of the drugs they carry.\textsuperscript{65} However, liposome-based drug delivery has drawbacks, often the liposome is cleared from the system before reaching the target cell and can elicit adverse immune responses.\textsuperscript{66} Therefore, EVs have come to the forefront as they are naturally occurring molecular carriers. Biologically derived EVs are less likely to elicit an allergic immune response or be prematurely cleared and are considered to have a better safety profile than synthetic carriers.\textsuperscript{67} Cell and gene-based therapies are of particular interest in inherited disorders such as CF.\textsuperscript{68} A difficulty in effective RNA therapy is the relative instability of the nucleotides in circulation.\textsuperscript{69} EVs are often chosen as delivery systems for RNA due to the aforementioned stability and role in communication.\textsuperscript{69} However, EV mediated drug delivery can come with inherent difficulties due to the heterogeneity of biologic production.\textsuperscript{70}

Mesenchymal stem cell (MSC) derived EVs have shown potential in the area of regenerative medicine.\textsuperscript{71} Studies using MSC-EVs in chronic lung disease are discussed further in this review. In the vaccine arena, research has been conducted using bacterial EVs in vaccine development. One such study by Olaya-Abril et al used EVs from Streptococcus pneumoniae to inoculate mice and conferred protection from pneumococcal infection.\textsuperscript{72}

<table>
<thead>
<tr>
<th>Technique</th>
<th>Principle</th>
<th>Advantage/disadvantage</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>Differential ultracentrifugation</td>
<td>EVs are isolated based on their sedimentation velocity in a centrifugal force</td>
<td>Currently most widely used and easy to perform, Difficulty achieving full separation of EV subcategories</td>
<td>148</td>
</tr>
<tr>
<td>Size exclusion</td>
<td>Separates EVs based on size</td>
<td>Well characterised kits available, Requires extensive postisolation processing</td>
<td>149</td>
</tr>
<tr>
<td>Affinity separation</td>
<td>A molecule with affinity to a surface marker on the EV is suspended in a resin or bead which ‘pulls’ EVs from complex matrices</td>
<td>Can be highly specific for EVs, Elution of the EV from the tagged resin requires harsh buffers which can degrade the EV membrane</td>
<td>150</td>
</tr>
<tr>
<td>Precipitation</td>
<td>High molecular weight polymers are complexed with EVs and isolated by either size or density-based methods</td>
<td>Reduces complexity of isolation protocol, Commercially available kit—ExoQuick, Requires postisolation decomplexation</td>
<td>53</td>
</tr>
<tr>
<td>Density ultracentrifugation</td>
<td>A form of ultracentrifugation (UC) where viscosity gradients are employed to create a cushion which separates molecules into defined layers</td>
<td>Greatly reduces copelleting substances such as cellular lipoproteins, Lower EV yields are often reported compared with differential UC</td>
<td>151</td>
</tr>
<tr>
<td>Microfluidic system</td>
<td>Acoustic, electric, optical, magnetic and immunoisolation of EVs from whole material</td>
<td>High purity isolation with qualitative and quantitative potential, Low volumes result in lower yield and throughput</td>
<td>16</td>
</tr>
</tbody>
</table>
Cystic fibrosis
CF is a life shortening disease caused by dysfunction in the cystic fibrosis transmembrane receptor resulting in impaired mucociliary clearance, inflammation and recurrent bacterial infection. 
A role for EVs as modulators of inflammatory cell activation in CF is emerging. An early study by Porro et al demonstrated that microparticles obtained from CF sputum are proinflammatory when injected into the murine lung and illicit a strong neutrophil response. Analysis of EVs isolated from BALF of PWCF and primarily ciliary dyskinesia demonstrated that disease state EVs contained higher levels of proteins involved in leukocyte chemotaxis than controls. We demonstrated that CF epithelial-derived EVs were enriched with inflammatory markers such as S100 A12 that could regulate neutrophil migration.

Our group and others have explored the biomarker potential of EVs in CF. Zulueta et al showed that the lipid profile of CF-EVs was significantly different than controls. Enhanced ceramide production leads to the release of EVs that export proinflammatory ceramides to the recipient cells, maintaining the unresolved inflammatory status of CF. Our group performed a study on EVs from BALF of four different age groups of PWCF and CF cell lines. We identified unique protein fingerprints and pathways between CF and control groups. Significant changes in EV number and protein content in CF adults undergoing exacerbation relative to controls were also observed. We also investigated the correlation between clinical markers such as IL-8 and NE found in BALF and protein expression in EVs from PWCF. A significant correlation between IL-8 levels and 29 EV proteins was found.

The therapeutic potential of lung MSC EVs was investigated as a potential anti-inflammatory treatment in CF. Using an in vitro model, Zulueta et al found that MSC EVs downregulated the expression of proinflammatory cytokines IL-1β and IL-6.

Asthma
Asthma is a chronic inflammatory disease of the airways with a complex pathophysiology. There are multiple endotypes of asthma making the development of diagnostic and therapeutic tools a challenge. EVs play a role in the pathology and progression of asthma by eliciting proinflammatory responses. EVs isolated from nasal lavage fluid of asthmatic donors exhibited chemotaxis of monocytes, natural killer cells and neutrophils. Profiling of EVs from BALF of patients with asthma identified proteins involved in toll-like receptor (TLR) signalling, orchestrating the inflammatory response. A study by Kim et al showed EVs from Staphylococcus aureus stimulated neutrophilic inflammation via TLR signalling. The functional effects EVs have in asthma has been recently investigated in several studies. Hough et al characterised the lipidome of EVs isolated from BALF of asthmatics and healthy controls, identifying unique lipid EV profiles in patients with asthma concluding that the altered lipidome could drive chronic inflammation. Hough et al also found positive correlations between plasma eosinophilia and EV particle count and IgE titre and particle count.

EVs from nasal polyps were found to have increased proteins associated with cell proliferation and thus remodelling of mucosal membranes. Treatment of human bronchial epithelial (HBE) cells with proinflammatory cytokines, specific to two subsets of asthma, T2 and T17 (T2 treated IL-4 and IL-13, T17 treated IL-17A and TNFα) increased EV release. EVs isolated from a murine model of asthma were found to have increased levels of immune cell-derived miRNA, such as miR-223 and miR-142a.

Interestingly, compared with controls, the dominant cell type
origin of EVs changed from largely epithelial cells to haematopoietic cells on allergen exposure.  

The use of EV miRNA cargo for potential biomarkers for pulmonary diseases has been discussed here concerning other conditions. Levänen et al. investigated the miRNA content of BALF EVs from patients with asthma. They found that there was a significant difference between asthmatic miRNA and that of controls and a significant correlation to EV miRNA and decreased FEV1. Similarly to the Héliot study of COPD, Levänen found that the let-7 family of nucleotides were among the most significantly downregulated in asthmatics. Mendes et al. used breath condensate to investigate a potential miRNA based platform for asthmatic endotyping. Let-7 and other miRNAs were shown in exhalate, in sufficient quantity and with a significant difference, to enable potential phenotyping of asthmatic children. Duarte et al. conducted one of the first investigations of EVs as biomarkers for asthma. They found that EVs levels were significantly increased in asthmatics and found strong but not significant indications of inflammatory markers. In the study by Ax et al., several genes and proteins were differentially expressed in the two models compared with controls. In a recent communication, Bahmer et al. indicated that miR-122-5p had potential to differentiate endotypes of asthma. They isolated miRNA from the plasma EVs of people with mild-to-moderate or severe eosinophilic asthma and healthy controls and found that counts of miR-122-5p positively correlated with blood eosinophils, neutrophils and lymphocytes. Investigating the same miRNA in sputum EVs from patients with asthma and healthy controls showed promising indications of an increase in asthmatics.

**Idiopathic pulmonary fibrosis**

IPF is a progressive lung disease that occurs due to increased fibrosis of lung tissue in response to chronic injury of the epithelium. Increased fibroblast activity and ECM accumulation in the lung are characteristics of the disease.

Cellular senescence is a feature of the epithelial response to IPF. EVs released from senescent cells have been linked to reduced reparative stem cell activity. As intercellular communicators, EVs recruit fibroblasts to the ECM of the IPF lung. Chanda et al. showed that fibroblast EVs had high ECM protein levels, including fibronectin. Lacy et al. indicated that normal lung EVs are enriched in antifibrotic prostaglandin and inhibit myofibroblast differentiation. They demonstrated that reduction of antifibrotic prostaglandin could trigger an exacerbation of IPF. Parim et al. conducted a study of IPF phenotype mouse lung EVs' profibrotic qualities. Using RNA-seq technology, they found that TGF-β and Wnt signaling pathways were upregulated in mouse lungs inoculated with IPF EVs. Martin-Medina et al. investigated the clinical relevance of EV-mediated WNT5A expression in IPF fibrogenesis. They found increased levels of WNT5A in EVs of people with IPF compared with non-IPF controls and a correlation between EV-associated CD81 and WNT5A.

Biomarker discovery in IPF is a clinically important field due to the disease's multiple origins. Makiguchi et al. tracked the expression of serum EV miR-21-5p across 41 patients with IPF, over 30 months. They observed that baseline levels of miR-21-5p could predict mortality in IPF over the 30-month period and could be used as an effective indicator of disease exacerbation. They found that there was a significant correlation between the levels of EV miR-21-5p and the rate of decline in predicted vital capacity of the lung over 6 months. Carleo et al. investigated potential biomarkers for familial IPF. They showed protein associated with clathrin-coated vesicles were part of a group of proteins upregulated in familial IPF. Nyck et al. have recently published two clinical studies investigating the role of EV-derived miRNA in the progression of IPF. Analysing the miRNA content of sputum-derived exosomes, the authors found seven upregulated miRNAs, and found a negative correlation between miR-142-3p and diffusing capacity of the lungs for carbon monoxide/alveolar volume. A further study by the group showed strong indications that upregulated miR-142-3p, derived from sputum and plasma exosomes of patients with IPF, were of macrophage origin. Guiot et al. also found that over expression of miR-142-3p could reduce expression of TGFβ-R1 and ultimately have an antifibrotic effect.

Using EV associated proteins for targeted therapies is relatively understudied. Marchetti et al. developed antiplasma-lemma vesicle-associated protein (PV1) antibodies to enhance therapeutic delivery to the lungs. The PV1 antibody was conjugated to an antifibrotic small molecule and showed increased localisation of the small molecule to the lung and kidneys. Wan et al. investigated bone marrow stem cell (BMSC) derived EVs as a potential treatment for IPF. They found that BMSC EVs with over-expressed miR-29b-3p could inhibit fibroblast activity. Mansouri et al. demonstrated the ability of MSC-EVs to alter the phenotype of bone-marrow monocyte, aiming to elicit the same anti-inflammatory phenotype in lung monocytes as a treatment for IPF. Dinh et al. used treated murine models of IPF with lung spheroid cell (LSC)-derived exosomes. This study found that LSC-exos were enriched with miRNAs largely conserved in stem cells and promoted lung repair in the murine IPF model.

**Lung cancer**

Lung cancer is the leading cause of cancer death worldwide. Although traditionally not considered a chronic disease, advances in biopharmaceuticals and surgical techniques for lung cancer treatment have created cohorts of long-term survivors. It is well established that EVs have numerous roles in lung cancer, including carcinogenesis, as biomarkers, as treatments and in treatment resistance. In the seminal paper by Fabbri et al., the authors investigated the prometastatic functionality of lung cancer-derived EV mRNA. They showed that mRNA could function as a ligand to TLR and induce inflammatory cells to create a metastatic niche. More recent studies have shown the significant and wide-ranging impact cancer EV-derived mRNA has on promoting cancer progression in the lung. Explorative approaches for integrating liquid biopsy into managing common cancer types have been developed, including 32 studies focusing on EVs. Here, we concentrate on EV studies that identified biomarkers between control and disease states and targets contributing to lung cancer progression.

Profiling EV proteins from sera in patients with early and advanced non-small cell lung carcinoma (NSCLC) identified fibronectin as a potential marker for clinical use. Qiao et al. identified several EV targets in metastatic lung cancer, functionally important in driving metastasis, including hepatocyte growth factor. Salivary exosomes from patients with lung cancer were isolated, and several candidate diagnostic biomarker proteins such as SPARC1L, ENO1, IQGAP1 and BPIFA, all of which have roles in the survival and proliferation of lung cancer. EVs derived from patient with lung ADC serum were analysed and compared with healthy controls. Four proteins could distinguish ADC from controls, SRGN, TPM3, THBS1 and HUWE1 are primarily vesicle-associated and support EVs
as enrichment sources for biomarkers. Cazzoli et al used EV microRNA to differentiate between ADC, granuloma and healthy controls. Comparing the small RNA cargo of ADC, NSCLC and control derived serum EVs showed differential expression of sRNA between the groups. Interestingly, comparison of sRNA from NSCLC cell lysate to serum EVs showed that miR-451a and miR-122-5p were significantly downregulated in lysate but significantly upregulated in EVs. A study of serum exosomes from metastatic and non-metastatic NSCLC showed that lipopolysaccharide-binding protein was a highly sensitive and specific marker for metastasis. Exosomes, isolated from pleural exudate of patients with lung cancer, contained protumour survival factors. The study found that exosomes from patients with lung cancer contained γ-glutamyl transpeptidase 1, which converts exogenous leucotrienes to a protumorigenic form. Choi et al recently investigated the correlation between circulating levels of EVs in pulmonary and peripheral blood and stages of lung cancer. They found that EVs were increased 10-fold in the peripheral blood of patients with lung cancer and 19-fold in the pulmonary blood, further they found a significant correlation between advancing cancer stages and EV counts in pulmonary blood.

Research into effective and safer cancer therapies is a continually growing field, as is research into keeping therapies potent and reducing resistance. Ma et al conducted a study into the role EVs have in chemo-resistance. Increased EV miR-425-3p was found in serum of patients with NSCLC during chemotherapeutic treatment. In vitro, chemoresistant EVs induced a resistant phenotype in untreated cells, miR-425-3p drove this process. There have been numerous studies in EV associated resistance, and they are reviewed in greater depth elsewhere.

As discussed previously, EVs can be drug carriers. Garofalo et al combined an oncolytic adenovirus and a chemotherapeutic within ADC EVs. Though the treatment showed accumulation in both the liver and lungs, a subsequent study by the group posited that an intravenous administration was preferential to intraperitoneal and could reduce accumulation. Similar to other respiratory diseases, cell-based therapies are also a viable therapeutic route in lung cancer.

The future of EVs and EV profiling in clinical respiratory medicine

There is a role for EVs in both clinical research and diagnosis. As evidenced in this review, EVs can provide new insight into the pathology of respiratory disease. Their role as cellular communicators is key to their contribution to pathogenesis. They coordinate ECM remodelling in COPD and IPF. In CF, they induce chemotaxis of leukocytes. They influence TLR signalling in asthma and cancer, orchestrating inflammatory responses and preparing metastatic sites. Profiling of EVs in the clinical arena could lead to a refined diagnosis for individual patients, directing the right therapies to the right patients. Response to treatments, particularly personalised treatments, often give insight into disease processes. The availability of clinical cohorts now receiving personalised treatments for respiratory diseases presents a unique opportunity to gain a greater understanding of EVs. Novel model systems such as organoids are being employed in the drive towards personalised medicine and offer opportunities in more physiologically relevant in vitro states to understand the functional role of EVs. However, challenges remain in the analysis of EVs within clinical studies. To date, studies of EVs in lung diseases have recruited modest numbers of patients. More large scale, prospective, multinational studies are required to precisely define the benefits of EV profiling in specific lung disorders. Where applicable the clinical parameters in EV studies discussed here have been stated above. However, further correlations between EV count or content and the clinical indicators of lung disease need to be performed. Additionally, the field lacks in clinical studies with the many investigations performed ex vivo, in vitro and using in vivo murine models.

A further issue is that pulmonary diseases are physiologically complex and occur on a spectrum of severity, which adds an additional layer of difficulty. Identifying robust biomarkers that can distinguish between exacerbated and steady states will be beneficial. Though caution is warranted, as the field of EV research grows rapidly, there is a tendency to focus on target cargo molecules while the broader landscape goes under-reported. Studies cited here have achieved this to some extent, but there is still much to be understood. Advances in omics technologies such as the advent of high-end mass spectrometers and new RNA sequencing technologies will enable deeper profiling of EVs enabling greater discovery of EV biomarkers. Identification of novel EV markers will also contribute towards better classification of EVs subpopulations addressing the challenge of EV heterogeneity.

Standardisation of EV methods is essential for the field to move forward and positively impact patient care. However, until there is consensus on isolation protocols analysts are required to balance the advantages and disadvantages, as discussed in table 3, of each method. Transparent reporting and centralising knowledge in EV research (EV-TRACK) platform is a collective effort to bring standardisation to EV studies by ‘scoring’ a study based on the techniques used in isolation and characterisation. Continued guidelines from organisations, such as ISERV, and evolution of platforms such as EV TRACK, will increase uniformity and improve standardisation. There are inherent difficulties in EV isolation that will require more than standardisation to resolve namely the large amounts of sample required to yield ‘useable’ quantities of EVs and the limitations of acquiring fresh samples in a longitudinal study. Though many groups, including our own, have gained valuable information from EV derived from deep-frozen samples the effects of freeze-thaw on the lipid-membrane are not fully understood.

The complexity and variety of chronic respiratory diseases call for more effective targeted therapies. MSC EVs have shown promise in reversing inflammatory environments of chronic lung disease. EVs have been shown to safe, effective carriers of drugs due to their specific cell targeting properties and stability. Although EVs have not elicited allergic responses in studies to date further investigations are needed to examine their immunogenicity profiles and potential to generate autoantibodies which could reduce the effectiveness of therapy.

The future for EV biology is bright and where the advent of new EV technologies will provide greater insights into different disease states in respiratory medicine ranging from early identification and diagnosis, to the prediction of exacerbation and effects of disease-modifying treatments.

Contributors The article was conceived by JAC, AT, PMN and SCD. AT and JAC were responsible for the initial draft preparation and revision. All authors were involved in reviewing each draft and approving the final manuscript.

Funding This work was supported by The National Children’s Research Centre under Project Grant No C17/13.

Competing interests None declared.

Patient consent for publication Not required.
REFERENCES


State of the art review


